MX355467B - Therapeutic antibodies. - Google Patents
Therapeutic antibodies.Info
- Publication number
- MX355467B MX355467B MX2013013911A MX2013013911A MX355467B MX 355467 B MX355467 B MX 355467B MX 2013013911 A MX2013013911 A MX 2013013911A MX 2013013911 A MX2013013911 A MX 2013013911A MX 355467 B MX355467 B MX 355467B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- human
- receptor
- c5ar
- therapeutic antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro- inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11168787 | 2011-06-06 | ||
US201161505137P | 2011-07-07 | 2011-07-07 | |
EP12159172 | 2012-03-13 | ||
PCT/EP2012/060524 WO2012168199A1 (en) | 2011-06-06 | 2012-06-04 | Therapeutic antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013013911A MX2013013911A (en) | 2014-01-24 |
MX355467B true MX355467B (en) | 2018-04-19 |
Family
ID=44315181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013013911A MX355467B (en) | 2011-06-06 | 2012-06-04 | Therapeutic antibodies. |
Country Status (1)
Country | Link |
---|---|
MX (1) | MX355467B (en) |
-
2012
- 2012-06-04 MX MX2013013911A patent/MX355467B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
MX2013013911A (en) | 2014-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015007751A (en) | Anti-gdf15 antibodies. | |
BR112013031198A8 (en) | therapeutic antibodies | |
PH12015500114B1 (en) | HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF | |
MX2011012691A (en) | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye. | |
WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
MX2018009524A (en) | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use. | |
UA107827C2 (en) | Antibody cd40 | |
TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
JO3199B1 (en) | Substituted 5-fluoro-1H-pyrazolopyridines and their use | |
WO2011143318A3 (en) | Anti-fgfr2 antibodies | |
UA104663C2 (en) | Antibody binding to cd127 | |
IN2014DN07149A (en) | ||
MX340953B (en) | Anti-gitr antibodies. | |
EA201390506A1 (en) | POLYPEPTIDES THAT BIND THE COMPONENT C5 OF THE HUMAN COMPLEX | |
WO2012006421A3 (en) | Diagnosis and treatment of breast cancer | |
WO2012006341A3 (en) | Anti-ron antibodies | |
MY165499A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
GB201109238D0 (en) | Antibodies | |
MX2023014921A (en) | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy. | |
MX2014001766A (en) | Neuregulin antibodies and uses thereof. | |
WO2014028668A3 (en) | Stem cell enhancing therapeutics | |
MX2013011421A (en) | Pyrazolo pyrimidine derivatives. | |
MX356745B (en) | A human monoclonal antibody against the vp1 protein of jc virus. | |
MX2015012580A (en) | The use of sdf-1 to mitigate scar formation. | |
EA201390314A1 (en) | SUPERNATANT, CONDITIONED BY ACTIVATED LEUKOCITES, AND ITS USE FOR THE HEALING OF THE RAS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |